MX2015001007A - Composicion de misoprostol. - Google Patents

Composicion de misoprostol.

Info

Publication number
MX2015001007A
MX2015001007A MX2015001007A MX2015001007A MX2015001007A MX 2015001007 A MX2015001007 A MX 2015001007A MX 2015001007 A MX2015001007 A MX 2015001007A MX 2015001007 A MX2015001007 A MX 2015001007A MX 2015001007 A MX2015001007 A MX 2015001007A
Authority
MX
Mexico
Prior art keywords
misprostol
composition
misoprostol
methods
î1⁄4g
Prior art date
Application number
MX2015001007A
Other languages
English (en)
Inventor
Barbara L Powers
Steven Robertson
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12178079.5A external-priority patent/EP2689781A1/en
Priority claimed from EP13150702.2A external-priority patent/EP2754442A1/en
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2015001007A publication Critical patent/MX2015001007A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere al uso de misoprostol para la inducción del trabajo de parto en una mujer embarazada, y en particular al uso de un dispositivo o inserto de suministro sostenido que contiene sustancialmente 200 µg de misoprostol para el uso intravaginal. El uso comprende métodos de terapia así como también composiciones para el uso en estos métodos.
MX2015001007A 2012-07-26 2013-07-25 Composicion de misoprostol. MX2015001007A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12178079.5A EP2689781A1 (en) 2012-07-26 2012-07-26 Misoprostol composition
EP13150702.2A EP2754442A1 (en) 2013-01-09 2013-01-09 Misoprostol for the induction of labour
PCT/EP2013/065767 WO2014016394A1 (en) 2012-07-26 2013-07-25 Misprostol composition

Publications (1)

Publication Number Publication Date
MX2015001007A true MX2015001007A (es) 2015-04-09

Family

ID=48856654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001007A MX2015001007A (es) 2012-07-26 2013-07-25 Composicion de misoprostol.

Country Status (12)

Country Link
US (2) US20150174139A1 (es)
EP (1) EP2877181A1 (es)
JP (2) JP2015522646A (es)
KR (1) KR20150038174A (es)
CN (1) CN104507482A (es)
AU (2) AU2013294960B2 (es)
CA (1) CA2879772A1 (es)
EA (1) EA031594B1 (es)
HK (1) HK1210966A1 (es)
IL (1) IL236357A0 (es)
MX (1) MX2015001007A (es)
WO (1) WO2014016394A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3166597A2 (en) 2014-07-11 2017-05-17 Azanta Danmark A/S Misoprostol dispersible tablet
DK2965750T3 (en) 2014-07-11 2017-10-16 Azanta Danmark As Misoprostol dispersible tablet
US20160008310A1 (en) 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU537741B2 (en) 1979-03-21 1984-07-12 British Technology Group Limited Controlled release compositions
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
CA2358556C (en) 1998-12-30 2006-10-31 Peter Joannes Coenders Diacetyl tartaric acid esters of mono- and diglycerides based on c12 to c22 fatty acids
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US7263335B2 (en) * 2004-07-19 2007-08-28 Purewave Networks, Inc. Multi-connection, non-simultaneous frequency diversity in radio communication systems
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
WO2006089561A1 (en) * 2005-02-23 2006-08-31 Abbas Abdelsalam Ghazi Pharmaceutical compositions containing organic acids useful for softening and ripening uterine cervix.
CN102939085B (zh) * 2010-06-11 2016-05-04 辉凌公司 阴道内施用米索前列醇

Also Published As

Publication number Publication date
US20170112854A1 (en) 2017-04-27
IL236357A0 (en) 2015-02-26
EA031594B1 (ru) 2019-01-31
EA201492238A1 (ru) 2015-06-30
KR20150038174A (ko) 2015-04-08
US20150174139A1 (en) 2015-06-25
EP2877181A1 (en) 2015-06-03
WO2014016394A1 (en) 2014-01-30
AU2013294960A1 (en) 2015-01-22
AU2013294960B2 (en) 2018-04-19
CA2879772A1 (en) 2014-01-30
CN104507482A (zh) 2015-04-08
AU2018206847A1 (en) 2018-08-09
JP2015522646A (ja) 2015-08-06
HK1210966A1 (en) 2016-05-13
JP2018184413A (ja) 2018-11-22

Similar Documents

Publication Publication Date Title
IN2015DN01156A (es)
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
GB201106743D0 (en) Novel compounds
GB201106750D0 (en) Novel compounds
MX2015010125A (es) Derivados de piridazinona-amidas.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX366899B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2021004211A (es) Composiciones vacuna.
MX2013004061A (es) Analogos de ciclosporina.
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
MA39710A (fr) Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
IN2014DN06104A (es)
MX2015012741A (es) Palbociclib deuterado.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MY172557A (en) Compositions for the treatment of hypertension and/or fibrosis
IN2014DN07326A (es)
MX2015001007A (es) Composicion de misoprostol.
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину